- Guide to PHARMACOLOGY
Synonyms: R-848 | R848
Compound class: Synthetic organic
Comment: Resiquimod (R-848) is a more potent derivative of the imidazoquinoline compound imiquimod . It acts as a TLR7 agonist.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Nat Immunol, 3 (2): 196-200. [PMID:11812998]
2. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Nat Immunol, 3 (6): 499. [PMID:12032557]
3. Larson P, Kucaba TA, Xiong Z, Olin M, Griffith TS, Ferguson DM. (2017)
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
ACS Med Chem Lett, 8 (11): 1148-1152. [PMID:29152046]
4. Stockfleth E, Hofbauer GFL, Reinhold U, Popp G, Hengge UR, Szeimies RM, Brüning H, Anliker M, Hunger T, Dummer R et al.. (2019)
Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
Br J Dermatol, 180 (2): 297-305. [PMID:30171698]